Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism TAAR1 agonists(Trace amine-associated receptor 1 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H22N4O2 |
InChIKeyXHHXGKRFUPEPFM-OAHLLOKOSA-N |
CAS Registry2133417-13-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ralmitaront | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizoaffective disorder | Phase 2 | ES | 04 Dec 2018 | |
Schizoaffective disorder | Phase 2 | US | 04 Dec 2018 | |
Schizoaffective disorder | Phase 2 | US | 04 Dec 2018 | |
Schizoaffective disorder | Phase 2 | UA | 04 Dec 2018 | |
Schizoaffective disorder | Phase 2 | ES | 04 Dec 2018 | |
Schizoaffective disorder | Phase 2 | JP | 04 Dec 2018 | |
Schizoaffective disorder | Phase 2 | UA | 04 Dec 2018 | |
Schizoaffective disorder | Phase 2 | JP | 04 Dec 2018 | |
Schizophrenia | Phase 2 | US | 04 Dec 2018 | |
Schizophrenia | Phase 2 | US | 04 Dec 2018 |
Phase 2 | 131 | placebo (Part A: Monotherapy (Placebo)) | ruupieshmp(ivlwmofmwb) = mvtfjvlymf snyvwxyfzb (hncjhvtzsd, ydovtnfwqi - ahruxtlfly) View more | - | 12 Aug 2024 | ||
(Part A: Monotherapy (150 mg)) | ruupieshmp(ivlwmofmwb) = vvpebkixvh snyvwxyfzb (hncjhvtzsd, pdhcfyufrw - bpxiggtitp) View more |